Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis (original) (raw)
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Pierre Charles MEBE
Annals of Internal Medicine, 2020
View PDFchevron_right
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis
Alan Salama
Arthritis & Rheumatism, 2009
View PDFchevron_right
Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis
S. Laurino
Arthritis & Rheumatism, 2012
View PDFchevron_right
Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID)
Raoul Bergner
The Journal of Rheumatology, 2012
View PDFchevron_right
Rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis
Luis Espinoza
Current Rheumatology Reports, 2009
View PDFchevron_right
Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
Andreas Kronbichler
Nephrology Dialysis Transplantation, 2015
View PDFchevron_right
Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients
H. Wedemeyer, Hermann Haller
Nephrology Dialysis Transplantation, 2008
View PDFchevron_right
Maintenance with Rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis
Vessel Plus
Vessel Plus, 2020
View PDFchevron_right
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab
D. Provan
Rheumatology, 2006
View PDFchevron_right
Maintenance with Rituximab in anti-neutrophil cytoplasm antibody vasculitis
Ayse Bag-Ozbek
Vessel Plus, 2020
View PDFchevron_right
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
Klaus Thuermel
Therapeutics and clinical risk management, 2015
View PDFchevron_right
Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis
Megan Griffith
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018
View PDFchevron_right
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
P. Tappenden
2014
View PDFchevron_right
Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis
Elisa Menegatti
American Journal of Nephrology, 2011
View PDFchevron_right
Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis
Romain Euvrard
Autoimmunity Reviews, 2020
View PDFchevron_right
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
F. Fervenza
New England Journal of Medicine, 2010
View PDFchevron_right
A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
Shahd Hafiz
Case Reports in Rheumatology, 2016
View PDFchevron_right
Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
shivani shah
Clinical Kidney Journal, 2017
View PDFchevron_right
Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment
Yannick Pouliot
Arthritis research & therapy, 2015
View PDFchevron_right
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis
F. Fervenza
2013
View PDFchevron_right
A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis; Case Report
Shahd Hafiz
View PDFchevron_right
Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides
Pierre Charles MEBE
La Presse Médicale, 2013
View PDFchevron_right
Is Rituximab Superior to Cyclophosphamide for ANCA-Associated Vasculitis for Induction of Remission, and with a Better Safety Profile?
Luis Adolfo Gomez Espinoza
Current Rheumatology Reports, 2010
View PDFchevron_right
Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort
pascale chasseur
Acta Clinica Belgica, 2019
View PDFchevron_right
Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future
Michael Walsh
Kidney International, 2007
View PDFchevron_right
Recent Advancements in the Management of Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review
Hadia Arzoun
Cureus, 2022
View PDFchevron_right
Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis
Megan Griffith
Nephrology Dialysis Transplantation, 2011
View PDFchevron_right
Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
Luca Quartuccio
Journal of Clinical Medicine
View PDFchevron_right
Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies
Eri Muso
Modern Rheumatology, 2020
View PDFchevron_right
Immunoglobulin Concentrations and Infection Risk Among Patients with ANCA-Associated Vasculitis Treated with Rituximab or Cyclophosphamide
Deborah Phippard
Arthritis & Rheumatism, 2011
View PDFchevron_right
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Vladimir Tesar
New England Journal of Medicine, 2010
View PDFchevron_right
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis
Pierre-Louis Carron
The New England journal of medicine, 2014
View PDFchevron_right